कंपनी का अवलोकन
Sana Biotechnology, Inc. operates as a biotechnology firm that specializes in utilizing engineered cells as therapeutic medicines within the United States market. The company has developed ex vivo and in vivo cell engineering platforms designed to address unmet treatment needs in specific therapeutic areas, such as type 1 diabetes and B cell mediated autoimmune diseases. This entity functions within the Healthcare sector and specifically the Biotechnology industry, which implies a focus on research and development of innovative biological treatments rather than traditional manufacturing. The company's market capitalization stands at $856.64M, employing a workforce of 142 individuals to support its operations. While specific annual revenue figures are not currently disclosed in the available data, the market cap suggests the company holds a mid-cap position, indicating a valuation that reflects significant potential for expansion alongside the inherent risks associated with early-stage biotechnology development. The scale of operations, supported by a substantial cash reserve, points to an organization investing heavily in its pipeline to achieve commercial milestones in the competitive biotech landscape.
वित्तीय स्वास्थ्य
The financial statements reveal a net income of $-244,166,000 over the trailing twelve-month period, while EBITDA is reported at $-178,208,000. The substantial gap between the negative net income and the less negative EBITDA indicates that interest expenses and other non-operating costs significantly impact the bottom line, a common characteristic for capital-intensive biotechnology firms before they generate substantial commercial revenue. Free cash flow stands at $-53,566,752, which signifies that the company is burning cash to fund its research and development activities rather than generating surplus liquidity from operations. Consequently, the company relies on existing capital reserves and external financing to maintain financial flexibility and continue its scientific endeavors. Analysis of the three profit margins shows that Gross Margin, Operating Margin, and Profit Margin are all reported at 0.0%, which indicates that the company has not yet achieved profitability or that current accounting treatments for revenue recognition result in zero margins until specific commercial thresholds are met. The balance sheet shows a cash position of $138.38M against total debt of $86.26M, resulting in a Debt to Equity ratio of 53.62, which suggests a highly leveraged capital structure relative to equity but mitigated by strong cash holdings. The current ratio of 1.89 indicates that the company possesses sufficient current assets to cover its short-term liabilities nearly twice over, suggesting adequate short-term liquidity despite the cash burn rate. Return on Equity is reported at -118.7% and Return on Assets at -26.0%, metrics that reveal management is currently deploying capital to generate negative returns, which is typical for pre-revenue biotech companies but highlights the lack of immediate operational efficiency.
मूल्यांकन आकलन
The trailing P/E ratio is listed as N/A due to negative earnings, while the forward P/E is calculated at -5.25, implying that the market expects earnings to remain negative or that valuation is based on non-earnings multiples. The Price to Book ratio is 5.32, indicating that the market values the company at more than five times its book value, which suggests a significant market premium assigned to the intangible assets and future potential of the drug pipeline. The Price to Sales and EV/EBITDA metrics are reported as N/A and -4.51 respectively, where the negative EV/EBITDA reinforces the company's unprofitable status and reliance on asset-heavy or cash-burning models rather than earnings-based valuation. The stock has traded within a 52-week range with a high of $6.55 and a low of $1.32, and given the current market context, the price sits in a volatile position relative to this historical range, reflecting the speculative nature of the asset. The Beta value of 2.06 indicates that the stock price is highly volatile, moving with more than double the magnitude of the broader market, which exposes investors to significant price swings during periods of market stress.
Growth & Income
Revenue Growth and Earnings Growth rates are both listed as N/A, preventing a direct comparison of earnings velocity against revenue expansion in the traditional sense. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which confirms that all available earnings and capital are reinvested into growth initiatives such as clinical trials and platform development rather than distributed to shareholders. This reinvestment strategy is standard for biotechnology firms that must prioritize research and development to reach commercialization milestones before they can sustainably pay dividends. The overall growth and income profile is characterized by high volatility and a complete absence of current income generation, relying entirely on future clinical success to drive shareholder value.